Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4944071 | 0.98 | TP53 (0.52) | TP53HPGDALDH1A1TLR8GLA | |
| SCHEMBL4940152 | 0.98 | HPGD (0.53) | TP53HPGDALDH1A1GLACYP1A2 | |
| SCHEMBL4945331 | 0.97 | ALDH1A1 (0.54) | TP53HPGDALDH1A1TLR8GLA | |
| SCHEMBL4944620 | 0.95 | TP53 (0.52) | TP53HPGDALDH1A1GLACYP1A2 | |
| SCHEMBL4944445 | 0.94 | HPGD (0.51) | TP53HPGDALDH1A1TLR8GLA | |
| SCHEMBL4947311 | 0.93 | TP53 (0.47) | TP53HPGDALDH1A1TLR8GLA | |
| SCHEMBL4946883 | 0.93 | TP53 (0.48) | TP53HPGDALDH1A1TLR8GLA | |
| SCHEMBL4937715 | 0.92 | ALDH1A1 (0.53) | TP53HPGDALDH1A1GLACYP1A2 | |
| SCHEMBL4941208 | 0.92 | HPGD (0.56) | TP53HPGDALDH1A1TLR8GLA | |
| SCHEMBL4945531 | 0.92 | TP53 (0.51) | TP53HPGDALDH1A1GLACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | claimed |
| EP-1458381-B1 | TRIAZOLES AS OXYTOCIN ANTAGONISTS | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-30 | — | — | EP | claimed |
| US-20050187275-A1 | Triazoles as oxytocin antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-08-25 | — | — | US | claimed |
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | disclosed |
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | disclosed |
| US-7468385-B2 | Triazoles as oxytocin antagonists | LABORATOIRES SERONO SA (CH) | 2008-12-23 | — | — | US | disclosed |
| US-20050187275-A1 | Triazoles as oxytocin antagonists | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187275-A1 | Triazoles as oxytocin antagonists | OXTR, AVPR2, AVPR1B | TP53 4351/4885HPGD 561/4885ALDH1A1 4091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.